Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.
Insider & Institutional Ownership
31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Adaptimmune Therapeutics and Cullinan Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adaptimmune Therapeutics | $60.28 million | 2.43 | -$113.87 million | ($0.22) | -2.60 |
| Cullinan Therapeutics | N/A | N/A | -$153.16 million | ($2.84) | -3.01 |
Analyst Recommendations
This is a summary of recent ratings and price targets for Adaptimmune Therapeutics and Cullinan Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adaptimmune Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
| Cullinan Therapeutics | 0 | 0 | 7 | 0 | 3.00 |
Adaptimmune Therapeutics currently has a consensus price target of $2.79, indicating a potential upside of 386.81%. Cullinan Therapeutics has a consensus price target of $32.50, indicating a potential upside of 279.67%. Given Adaptimmune Therapeutics’ higher probable upside, equities research analysts plainly believe Adaptimmune Therapeutics is more favorable than Cullinan Therapeutics.
Volatility & Risk
Adaptimmune Therapeutics has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500.
Profitability
This table compares Adaptimmune Therapeutics and Cullinan Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adaptimmune Therapeutics | -25.43% | -74.15% | -15.09% |
| Cullinan Therapeutics | N/A | -26.54% | -25.32% |
Summary
Adaptimmune Therapeutics beats Cullinan Therapeutics on 8 of the 12 factors compared between the two stocks.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
